Critical Survey: MindWalk (NASDAQ:HYFT) versus BetterLife Pharma (OTCMKTS:PVOTF)

MindWalk (NASDAQ:HYFT) and BetterLife Pharma (OTCMKTS:PVOTF) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability.

Analyst Recommendations

This is a breakdown of recent ratings for MindWalk and BetterLife Pharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	1	1	2	1	2.60
BetterLife Pharma	0	0	0	0	0.00

MindWalk currently has a consensus price target of $5.00, suggesting a potential upside of 226.80%. Given MindWalk’s stronger consensus rating and higher probable upside, research analysts plainly believe MindWalk is more favorable than BetterLife Pharma.

Earnings and Valuation

This table compares MindWalk and BetterLife Pharma”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MindWalk	$17.59 million	4.02	-$21.69 million	($0.20)	-7.65
BetterLife Pharma	N/A	N/A	-$14.78 million	N/A	N/A

BetterLife Pharma has lower revenue, but higher earnings than MindWalk.

Profitability

This table compares MindWalk and BetterLife Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MindWalk	-66.79%	-69.37%	-39.74%
BetterLife Pharma	N/A	-205.15%	-147.23%

Insider & Institutional Ownership

6.7% of MindWalk shares are held by institutional investors. 6.8% of MindWalk shares are held by company insiders. Comparatively, 34.8% of BetterLife Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

MindWalk beats BetterLife Pharma on 8 of the 12 factors compared between the two stocks.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

About BetterLife Pharma

BetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada.